Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Cryo-electron microscopy structure of the glucagon receptor with a dual-agonist peptide.

Tytuł:
Cryo-electron microscopy structure of the glucagon receptor with a dual-agonist peptide.
Autorzy:
Chang R; School of Pharmacy, Shanghai Medical College, Fudan University, Shanghai, China.
Zhang X; Monash Institute of Pharmaceutical Sciences, Drug Discovery Biology, Monash University, Parkville, Victoria, Australia.
Qiao A; The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.; University of Chinese Academy of Sciences, Beijing, China.
Dai A; The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.; The National Center for Drug Screening, Shanghai, China.
Belousoff MJ; Monash Institute of Pharmaceutical Sciences, Drug Discovery Biology, Monash University, Parkville, Victoria, Australia.
Tan Q; The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.; University of Chinese Academy of Sciences, Beijing, China.
Shao L; The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.; University of Chinese Academy of Sciences, Beijing, China.; School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Zhong L; The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.; University of Chinese Academy of Sciences, Beijing, China.
Lin G; The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.; University of Chinese Academy of Sciences, Beijing, China.; School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Liang YL; Monash Institute of Pharmaceutical Sciences, Drug Discovery Biology, Monash University, Parkville, Victoria, Australia.
Ma L; The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Han S; The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Yang D; The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.; The National Center for Drug Screening, Shanghai, China.
Danev R; Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Wang MW; School of Pharmacy, Shanghai Medical College, Fudan University, Shanghai, China .; The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.; University of Chinese Academy of Sciences, Beijing, China.; The National Center for Drug Screening, Shanghai, China.; School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Wootten D; Monash Institute of Pharmaceutical Sciences, Drug Discovery Biology, Monash University, Parkville, Victoria, Australia .
Wu B; The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China .; University of Chinese Academy of Sciences, Beijing, China.; School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Sexton PM; Monash Institute of Pharmaceutical Sciences, Drug Discovery Biology, Monash University, Parkville, Victoria, Australia .
Źródło:
The Journal of biological chemistry [J Biol Chem] 2020 Jul 10; Vol. 295 (28), pp. 9313-9325. Date of Electronic Publication: 2020 May 05.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: 2021- : [New York, NY] : Elsevier Inc. on behalf of American Society for Biochemistry and Molecular Biology
Original Publication: Baltimore, MD : American Society for Biochemistry and Molecular Biology
MeSH Terms:
Cryoelectron Microscopy*
Receptors, Glucagon*/agonists
Receptors, Glucagon*/chemistry
Receptors, Glucagon*/ultrastructure
Peptides/*chemistry
Animals ; Glucagon-Like Peptide-1 Receptor/agonists ; Glucagon-Like Peptide-1 Receptor/chemistry ; Glucagon-Like Peptide-1 Receptor/ultrastructure ; Humans ; Protein Domains ; Protein Structure, Quaternary
References:
Mol Cell. 2020 Feb 6;77(3):669-680.e4. (PMID: 32004470)
Science. 2019 Apr 12;364(6436):148-153. (PMID: 30975883)
Nature. 2013 Jul 25;499(7459):444-9. (PMID: 23863937)
Nat Methods. 2019 Jun;16(6):471-477. (PMID: 31086343)
Mol Cell Endocrinol. 2019 May 15;488:1-13. (PMID: 30930094)
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501. (PMID: 20383002)
Acta Crystallogr D Struct Biol. 2019 Oct 1;75(Pt 10):861-877. (PMID: 31588918)
Nature. 2017 Jun 8;546(7657):248-253. (PMID: 28538729)
J Pept Sci. 2011 Apr;17(4):270-80. (PMID: 21294225)
ACS Pharmacol Transl Sci. 2019 Jan 11;2(1):31-51. (PMID: 32219215)
Nature. 2018 Sep;561(7724):492-497. (PMID: 30209400)
Cell Res. 2020 May;30(5):436-445. (PMID: 32047270)
Nat Med. 2015 Jan;21(1):27-36. (PMID: 25485909)
Mol Metab. 2013 Dec 14;3(3):241-51. (PMID: 24749050)
J Clin Endocrinol Metab. 2020 Mar 1;105(3):. (PMID: 31608926)
Chem Rev. 2017 Jan 11;117(1):111-138. (PMID: 27040440)
Nature. 2017 Jun 8;546(7657):259-264. (PMID: 28514451)
Mol Pharmacol. 2016 Mar;89(3):335-47. (PMID: 26700562)
Nat Methods. 2017 Mar;14(3):290-296. (PMID: 28165473)
Am J Physiol Endocrinol Metab. 2012 Jul 15;303(2):E265-71. (PMID: 22621866)
J Struct Biol. 2016 Jan;193(1):1-12. (PMID: 26592709)
Peptides. 2020 Mar;125:170225. (PMID: 31786282)
Nature. 2018 Mar 1;555(7694):121-125. (PMID: 29466332)
Endocr Rev. 2018 Oct 1;39(5):719-738. (PMID: 29905825)
Mol Pharmacol. 2010 Sep;78(3):394-401. (PMID: 20573782)
ACS Pharmacol Transl Sci. 2020 Mar 20;3(2):263-284. (PMID: 32296767)
Nature. 2017 Jun 1;546(7656):118-123. (PMID: 28437792)
Lancet. 2018 Jun 30;391(10140):2607-2618. (PMID: 29945727)
Diabetes Obes Metab. 2019 Jan;21(1):120-128. (PMID: 30091218)
Diabetes Obes Metab. 2020 Apr;22(4):640-647. (PMID: 31808298)
Obesity (Silver Spring). 2012 Aug;20(8):1566-71. (PMID: 22421924)
Nature. 2011 Jul 19;477(7366):549-55. (PMID: 21772288)
J Comput Chem. 2005 Dec;26(16):1781-802. (PMID: 16222654)
J Biol Chem. 2018 Jun 15;293(24):9370-9387. (PMID: 29717000)
Diabetes Metab Syndr Obes. 2020 Feb 18;13:433-438. (PMID: 32110076)
Mol Cell. 2020 Feb 6;77(3):656-668.e5. (PMID: 32004469)
Nat Struct Mol Biol. 2020 Mar;27(3):274-280. (PMID: 32157248)
Int Rev Cell Mol Biol. 2016;326:279-341. (PMID: 27572131)
Br J Pharmacol. 2001 Aug;133(8):1249-54. (PMID: 11498510)
Nat Methods. 2013 Jun;10(6):584-90. (PMID: 23644547)
Elife. 2018 Nov 09;7:. (PMID: 30412051)
Nat Rev Endocrinol. 2015 Jun;11(6):329-38. (PMID: 25850661)
Diabetes Obes Metab. 2018 Feb;20 Suppl 1:22-33. (PMID: 29364586)
Nature. 2020 Jan;577(7790):432-436. (PMID: 31915381)
Nat Chem Biol. 2009 Oct;5(10):749-57. (PMID: 19597507)
Cell. 2016 Jun 16;165(7):1632-1643. (PMID: 27315480)
Diabetologia. 2017 Oct;60(10):1851-1861. (PMID: 28733905)
Br J Pharmacol. 2019 Dec;176 Suppl 1:S21-S141. (PMID: 31710717)
Commun Biol. 2019 Jun 19;2:218. (PMID: 31240256)
Nat Methods. 2017 Apr;14(4):331-332. (PMID: 28250466)
Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5211-6. (PMID: 23479653)
ACS Pharmacol Transl Sci. 2018 Jul 26;1(1):12-20. (PMID: 32219201)
ACS Pharmacol Transl Sci. 2018 Sep 07;1(2):73-83. (PMID: 32219204)
Science. 2020 Mar 20;367(6484):1346-1352. (PMID: 32193322)
Contributed Indexing:
Keywords: G protein–coupled receptor (GPCR); GLP-1 receptor; cryo-electron microscopy; dual agonist; glucagon; glucagon receptor; glucagon-like peptide-1 receptor; metabolic disorder; peptide 15 (P15); single particle analysis; structural biology; structure-function
Molecular Sequence:
PDB 6LMK; 5VAI
Substance Nomenclature:
0 (GLP1R protein, human)
0 (Glucagon-Like Peptide-1 Receptor)
0 (Peptides)
0 (Receptors, Glucagon)
Entry Date(s):
Date Created: 20200507 Date Completed: 20210113 Latest Revision: 20210711
Update Code:
20240105
PubMed Central ID:
PMC7363120
DOI:
10.1074/jbc.RA120.013793
PMID:
32371397
Czasopismo naukowe
Unimolecular dual agonists of the glucagon (GCG) receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R) are a new class of drugs that are potentially superior to GLP-1R-specific agonists for the management of metabolic disease. The dual-agonist, peptide 15 (P15), is a glutamic acid 16 analog of GCG with GLP-1 peptide substitutions between amino acids 17 and 24 that has potency equivalent to those of the cognate peptide agonists at the GCGR and GLP-1R. Here, we have used cryo-EM to solve the structure of an active P15-GCGR-G s complex and compared this structure to our recently published structure of the GCGR-G s complex bound to GCG. This comparison revealed that P15 has a reduced interaction with the first extracellular loop (ECL1) and the top of transmembrane segment 1 (TM1) such that there is increased mobility of the GCGR extracellular domain and at the C terminus of the peptide compared with the GCG-bound receptor. We also observed a distinct conformation of ECL3 and could infer increased mobility of the far N-terminal His-1 residue in the P15-bound structure. These regions of conformational variance in the two peptide-bound GCGR structures were also regions that were distinct between GCGR structures and previously published peptide-bound structures of the GLP-1R, suggesting that greater conformational dynamics may contribute to the increased efficacy of P15 in activation of the GLP-1R compared with GCG. The variable domains in this receptor have previously been implicated in biased agonism at the GLP-1R and could result in altered signaling of P15 at the GCGR compared with GCG.
Competing Interests: Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.
(© 2020 Chang et al.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies